Communiqué from the Extraordinary General Meeting of Cell Impact AB (publ)

Cell Impact’s Extraordinary General Meeting approved a SEK 38.3 million rights issue of up to 294,584,745 new shares at SEK 0.13 per share (1:1 subscription rights), with record date 4 Feb 2026 and subscription period 6–20 Feb 2026. The meeting also approved a share capital reduction (to achieve a quota value of SEK 0.10), a bonus issue, amendments to the articles of association, and an authorization to issue shares to guarantors and warrants to the bridge-loan lender. The transaction is dilutive but secures near-term funding and authorization flexibility to support the company’s patented Cell Impact Forming™ technology and operations in the fuel-cell/electrolyzer market.

Analysis

Market structure: The SEK 38.3m rights issue at SEK 0.13/share is a clear defensive capital raise that transfers value to new/participating shareholders and guarantors while massively diluting incumbents; suppliers of advanced flow plates (small-cap OEMs) are likely losers as financing stress reduces near-term purchasing power, while larger, better-funded electrolyzer/fuel‑cell OEMs (e.g., NEL.OL, BLDP, PLUG) gain relative pricing power and order capture. The issuance signals constrained liquidity rather than immediate demand collapse — short-term supply of Cell Impact stock will increase substantially, pressuring the share price into or below the SEK 0.13 floor unless rights subscription is near-universal.

Risk assessment: Tail risks include a failed or under-subscribed rights issue leading to creditor enforcement or insolvency within 3–6 months, patent litigation or technical failure in scale-up that would render Cell Impact Forming™ non‑commercial (low probability, high impact). Immediate risk (days) centers on rights trading and information asymmetry; short-term (weeks/months) on subscription uptake and bridge-loan warrant dilution; long-term (quarters/years) on market adoption of their forming tech vs incumbent methods. Hidden dependencies: access to industrial customers and EU H2 grants; losing one strategic contract could wipe out projected revenue runway.

Trade implications: Avoid unilateral long exposure to Cell Impact pre-issuance; consider a tactical short or synthetic short sized 1–2% NAV targeting a 30–70% downside catalyst window (6–10 weeks) if subscription coverage <80%. Implement a pair trade: short Cell Impact vs long Nel ASA (NEL.OL) 1:2 to express relative operational/financial strength. For broader hydrogen exposure, overweight NEL.OL and Ballard (BLDP) by +2–4% overweight, hedge with 3–6 month protective puts (example: buy 3‑month ATM puts on PLUG to cap downside).

Contrarian angles: Consensus views the raise as weak — but if rights are heavily guaranteed by long-term guarantors receiving shares/warrants, contagion could be muted and post-issue free‑float reduced, enabling a quick squeeze if order wins materialize. The market may be over-discounting IP value: if Cell Impact secures a multi‑year supply contract or EU subsidy within 3–6 months, dilution pain could be offset by rapid revenue scaling. Watch for warrant exercise terms and guarantor lockups; these determine whether post-issue ownership is stable or immediate sell pressure resumes.

Key Decisions for Investors

• Establish a tactical short position in Cell Impact (Nasdaq First North Growth Market) sized 1–2% of NAV before 20 Feb, with a profit target of 40–60% and stop-loss at 20% adverse move; unwind if subscription coverage >90% or if company announces strategic anchor investor within 2 weeks post-subscription.
• Implement a pair trade: short Cell Impact (1 unit) vs long Nel ASA (NEL.OL, 2 units) sized to be delta-neutral for hydrogen theme exposure; hold 6–12 months, rebalance if Nel announces new orders or Cell Impact announces >50% subscription uptake.
• Rotate 2–4% weight from small-cap fuel‑cell/electrolyzer suppliers into NEL.OL and BLDP (Ballard) over next 10 trading days; hedge sector tail-risk by buying 3‑6 month ATM puts on PLUG (1–2% NAV cost cap) to limit downside from technology adoption setbacks.
• If rights are tradable, consider buying rights and subscribing pro rata only if you can commit at SEK 0.13 and your cost basis post-subscription stays below SEK 0.20; otherwise avoid participation—use a hard threshold: participate only if you can acquire >5% post-issue ownership with clear order pipeline within 6 months.
• Monitor three binary triggers within 7–30 days: announced subscription coverage (%) at completion (<70% = increase short sizing), disclosure of guarantor lock-up length (>6 months = reduce short), and any announced EU/industrial contracts (≥€1m revenue pipeline = reassess long thesis).